Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Toshio Shikano"'
Autor:
Hiroya Taniguchi, Keisuke Uehara, Goro Nakayama, Hiroshi Nakayama, Toshisada Aiba, Norifumi Hattori, Masato Kataoka, Yasuyuki Nakano, Yoshihisa Kawase, Osamu Okochi, Hiroshi Matsuoka, Setsuo Utsunomiya, Eiji Sakamoto, Yoshinori Mori, Shinichi Umeda, Toshio Shikano, Koji Komori, Masahiro Tajika, Shigenori Kadowaki, Kei Muro, Yasushi Yatabe
Publikováno v:
Translational Oncology, Vol 13, Iss 7, Pp 100786- (2020)
BACKGROUND: Primary tumor location is a critical prognostic factor that also impacts the efficacy of anti-epidermal growth factor receptor (EGFR) therapy in wild-type RAS (KRAS/NRAS) metastatic colorectal cancer (CRC). However, the association betwee
Externí odkaz:
https://doaj.org/article/ef4cda05f303454c8cea476dee81c494
Autor:
Kazuhiro Yoshida, Wataru Ichikawa, Toshio Shikano, Nobuyuki Musha, Masato Kataoka, Masahiro Takeuchi, Hitoshi Ojima, Tsunenobu Takase, Kazushige Shibahara, Sang-Woong Lee, Atsushi Ishiguro, Masashi Fujii, Yoshinori Sakai, Taisei Kimura, Mitsugu Kochi, Yoshihiro Kakeji, Takeshi Sano, Yasuhiro Kodera
Publikováno v:
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 25(1)
The second planned interim analysis (median follow-up 12.5 months) in a phase III trial of postoperative adjuvant chemotherapy for stage III gastric cancer revealed significant improvement in relapse-free survival (RFS) for S-1 plus docetaxel over S-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76f6b8148c4b0ef749bee822c9b7faed
https://pubmed.ncbi.nlm.nih.gov/34351555
https://pubmed.ncbi.nlm.nih.gov/34351555
Autor:
Kei Muro, Yasuyuki Nakano, Shigenori Kadowaki, Goro Nakayama, Shinichi Umeda, Setsuo Utsunomiya, Yoshinori Mori, Toshisada Aiba, Osamu Okochi, Norifumi Hattori, Toshio Shikano, Yoshihisa Kawase, Masato Kataoka, Yasushi Yatabe, Hiroshi Nakayama, Hiroya Taniguchi, Keisuke Uehara, Masahiro Tajika, Hiroshi Matsuoka, Koji Komori, Eiji Sakamoto
Publikováno v:
Translational Oncology
Translational Oncology, Vol 13, Iss 7, Pp 100786-(2020)
Translational Oncology, Vol 13, Iss 7, Pp 100786-(2020)
BACKGROUND: Primary tumor location is a critical prognostic factor that also impacts the efficacy of anti-epidermal growth factor receptor (EGFR) therapy in wild-type RAS (KRAS/NRAS) metastatic colorectal cancer (CRC). However, the association betwee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0731f847d73adcfb5fadc6de56111cd4
http://europepmc.org/articles/PMC7232108
http://europepmc.org/articles/PMC7232108
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 79:1453-1458
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd681de93770bab165a994a1142f40c0
https://doi.org/10.3919/jjsa.79.1453
https://doi.org/10.3919/jjsa.79.1453
Autor:
Toshio Shikano, Hiroshi Kojima, Hiroshi Nakayama, Koji Torii, Daisuke Kobayashi, Yasuhiro Kodera, Kiyoshi Ishigure, Yoshinari Mochizuki, Yoshihisa Kawase
Publikováno v:
International journal of clinical oncology. 25(10)
91 Background: Nab-paclitaxel (nab-PTX) is a candidate as second-line chemotherapy for gastric cancer, with the response rate (RR) of 28% and overall survival (OS) of 9.2 months in that setting in Japan (J-0200). Adverse events (AE) of grade 3 or mor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfe913589a5c7250aadba0c5e6df7c80
https://pubmed.ncbi.nlm.nih.gov/32567012
https://pubmed.ncbi.nlm.nih.gov/32567012
Autor:
Takehiro Hachisuka, Toshio Shikano, Toshihiro Mori, Kosuke Tochigi, Yoshimasa Hashimoto, Nobuhiko Kurata
Publikováno v:
The Japanese Journal of Gastroenterological Surgery. 49:569-577
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cff04fbf317a559d49145ef38f46c507
https://doi.org/10.5833/jjgs.2015.0155
https://doi.org/10.5833/jjgs.2015.0155
Autor:
Toyone Kikumori, Hiroyuki Sugimoto, Yoshihiro Hotta, Toru Ichinose, Saori Fukuda, Shuji Nomoto, Shin Takeda, Naoko Tsurumaru, Yoko Nishikawa, Maki Tanaka, Suguru Yamada, Akimasa Nakao, Kazuo Yamamura, Toshio Shikano, Tevfik Tolga Sahin, Yusuke Koide, Zhiwen Wu, Gewen Tan, Yasuhiro Kodera, Akiyuki Kanzaki, Hideki Kasuya, Toshie Kuwahara, Tsutomu Fujii
Publikováno v:
International Journal of Cancer. 136:1718-1730
Breast cancer is one of the most common and feared cancers faced by women. The prognosis of patients with advanced or recurrent breast cancer remains poor despite refinements in multimodality therapies involving chemotherapeutic and hormonal agents.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e078d7e35aa9973a70ef4dc3e1a6442
https://doi.org/10.1002/ijc.29163
https://doi.org/10.1002/ijc.29163
Autor:
Yasuhiro Kodera, Hiroyuki Sugimoto, Yoko Nishikawa, Kazuo Yamamura, Tevfik Tolga Sahin, S. Nomoto, Naohiro Nomura, Akimasa Nakao, Hideki Kasuya, Takashi Shirota, Makoto Misawa, Saori Fukuda, Gewen Tan, Tsutomu Fujii, Suguru Yamada, Akiyuki Kanzaki, Toshio Shikano, S. Takeda
Publikováno v:
Cancer Gene Therapy. 19:292-298
Although several studies have reported that locally administering oncolytic viruses effectively targets malignancies, the efficacy of systemically administered oncolytic viruses is restricted. Recently, however, it was reported that systemic administ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33a8f3c0cf6bd4424a12447f98b5f30b
https://doi.org/10.1038/cgt.2011.91
https://doi.org/10.1038/cgt.2011.91
Autor:
Kazuo Yamamura, Toyone Kikumori, Takashi Sugae, Yukihiro Nishiyama, Hideki Kasuya, S. Nomoto, Yasuhiro Kodera, Tan Gewen, Hiroyuki Sugimoto, Akimasa Nakao, Toshio Shikano, Tsuneo Imai, S. Takeda, Akiyuki Kanzaki, Naohiro Nomura, Tevfik Tolga Sahin, Tsutomu Fujii
Publikováno v:
Cancer Gene Therapy. 19:229-237
Oncolytic viruses are a promising method of cancer therapy, even for advanced malignancies. HF10, a spontaneously mutated herpes simplex type 1, is a potent oncolytic agent. The interaction of oncolytic herpes viruses with the tumor microenvironment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9c70671f9066b394b54a31da0c537a6
https://doi.org/10.1038/cgt.2011.80
https://doi.org/10.1038/cgt.2011.80
Autor:
Naohiro Nomura, Akimasa Nakao, Toshio Shikano, Naohito Kanazumi, Makoto Misawa, Hiroyuki Sugimoto, Hideki Kasuya, Shin Takeda, Yoko Nishikawa, Takashi Shirota, Shuji Nomoto, Akiyuki Kanzaki, Suguru Yamada, Tevfik Tolga Sahin, Tsutomu Fujii
Publikováno v:
Current Cancer Drug Targets. 11:111-122
Purpose: Oncolytic viral therapy is a newly developed modality to treat tumors. Many clinical trials worldwide have examined the efficacy of locally injected oncolytic viruses. However, systemic intravascular injections are limited by the humoral imm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7c5c7028c4c152063b37672d12cbd7a
https://doi.org/10.2174/156800911793743673
https://doi.org/10.2174/156800911793743673